Lipoprotein lipase: A bioinformatics criterion for assessment of mutations as a risk factor for cardiovascular disease

Proteins: Structure, Function and Genetics

Volumn 70, Issue 3, 2008, Pages 855-862

  Glisic, Sanja ^a   Arrigo, Patrizio ^b   Alavantic, Dragan ^a   Perovic, Vladimir ^a   Prljic, Jelena ^a   Veljkovic, Nevena ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CNR   (Italy)

Author keywords

CVD; Informational spectrum method; LPL; Mutational analysis; SNP

Indexed keywords

APOLIPOPROTEIN C2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; MUTANT PROTEIN; NUCLEOTIDE; TRIACYLGLYCEROL;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BIOINFORMATICS; CARDIOVASCULAR DISEASE; DISEASE PREDISPOSITION; ENZYME ACTIVITY; GENE MUTATION; LIPID METABOLISM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SPECTROSCOPY; VIRTUAL SPECTROSCOPY;

AMINO ACID SEQUENCE; ANIMALS; APOLIPOPROTEINS; CARDIOVASCULAR DISEASES; COMPUTATIONAL BIOLOGY; DIMERIZATION; HUMANS; LIPOPROTEIN LIPASE; MODELS, MOLECULAR; MUTATION; RISK FACTORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 38549089000     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.21581     Document Type: Article

References (40)

1. Osborne JC, Jr, Bengtsson-Olivecrona G, Lee NS, Olivecrona T. Studies on inactivation of lipoprotein lipase: role of the dimer to monomer dissociation. Biochemistry 1985;24:5606-5611.
2. Babirak SP, Iverius PH, Fujimoto WY, Brunzell JD. Detection and characterization of the heterozygote state for lipoprotein lipase deficiency. Arteriosclerosis 1989;9:326-334.
3. Hokanson J, Austin M. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-219.
4. Barter PJ, Rye KA. High density lipoproteins and coronary heart disease. Atherosclerosis 1996;121:1-12.
5. Goldberg IJ, Merkel M. Lipoprotein lipase: physiology, biochemistry, and molecular biology. Front Biosci 2001;6:d388-d405.
6. Veljkovic V, Cosic I, Dimitrijevic B, Lalovic D. Is it possible to analyze DNA and protein sequence by the method of digital signal processing? IEEE Trans Biomed Eng BME 1985;32:337-341.
7. Veljkovic V, Cosic I. A novel method of protein analysis for prediction of biological function. Cancer Biochem Biophys 1987;9:9-149.
8. Cosic I. The resonant recognition model of macromolecular bioreactivity: theory and application. Berlin: Birkhauser Verlag; 1997.
9. Veljkovic V, Veljkovic N, Este JA, Huther A, Dietrich U. Application of the EIIP/ISM bioinformatics concept in development of new drugs. Curr Med Chem 2007;14:441-453.
10. Veljkovic V. A theoretical approach to preselection of carcinogens and chemical carcinogenesis. New York: Gordon and Breach; 1980.
11. Veljkovic V, Slavic I. Simple general-model pseudopotential. Phys Rev Lett 1972;29:105-107.
12. Veljkovic V. The dependence of the Fermi energy on the atomic number. Phys Lett A 1973;45:41-42.
13. Lazovic J. Selection of amino acid parameters for Fourier transform-based analysis of proteins. Comput Appl Biosci 1996;12:553-562.
14. Cosic I, Nesic D, Pavlovic M, Williams R. Enhancer binding proteins predicted by informational spectrum method. Biochem Biophys Res Commun 1986;141:831-838.
15. Skerl V, Pavlovic M. Thymopoetins and long postsynaptic neurotoxins share common information in their primary structures. FEBS Lett 1988;239:1411-1416.
16. Veljkovic V, Metlas R. Identification of nanopeptide from HTLV3, LAV and ARV-2 envelope gp120 determining binding to T4 cell surface protein. Cancer Biochem Biophys 1988;10:91-106.
17. Cosic I, Nesic D. Prediction of hot spots in SV40 enhancer and relation with experimental data. Eur J Biochem 1987;170:247-252.
18. Cosic I, Pavlovic M, Vojisavljevic V. Prediction of hot spots in interleukin-2 based on informational spectrum characteristics of growth regulating factor. Biochemie 1989;71-333-339.
19. Cosic I, Hearn MT. Hot spot amino acid distribution in Ha-ras oncogene product p21: relationship to guanine binding site. J Mol Recognit 1991;4:57-62.
20. Veljkovic N, Branch DR, Metlas R, Prljic J, Vlahovicek K, Pongor S, Veljkovic V. Design of peptide mimetics of HIV-1 gp120 for prevention and therapy of HIV disease. J Pept Res 2003;62:158-166.
21. Veljkovic N, Perovic V. In silico criterion for prediction of effects of p53 gene missense mutations on p53-Mdm2 feedback loop. Protein Pept Lett 2006;13:807-814.
22. Sunyaev S, Ramensky V, Koch I, Lathe W, III, Kondrashov AS, Bork P. Prediction of deleterious human alleles. Hum Mol Genet 2001;10:591-597.
23. Arrigo P, Scartezzini P, Romano P. AgeWa: an integrated approach for antisense experiment design. IEEE Trans Nanobiosci 2002;1:167-171.
24. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-4680.
25. Doolittle RF. Similar amino acid sequences chance or common ancestry. Science 1981;214:149-159.
26. Ng P, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res 2001;11:863-874.
27. Sunyaev S, Ramensky V, Koch I, Lathe W, III, Kondrashov AS, Bork P. Prediction of deleterious human alleles. Hum Mol Genet 2001;10:591-597.
28. Yue P, Melamud E, Moult J. SNPs3D: candidate gene and SNP selection for association studies. BMC Bioinformatics 2006;22:166.
29. Bao L, Zhou M, Cui Y. nsSNPAnalyzer: identifying disease-associated nonsynonymous single nucleotide polymorphisms. Nucleic Acids Res 2005;33:W480-W482.
30. Gagne SE, Larson MG, Pimstone SN, Schaefer EJ, Kastelein JJ, Wilson PW, Ordovas JM, Hayden MR. A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study. Clin Genet 1999;55:450-454.
31. Chen W, Srinivasan SR, Elkasabany A, Ellsworth DL, Boerwinkle E, Berenson GS. Influence of lipoprotein lipase serine 447 stop polymorphism on tracking of triglycerides and HDL cholesterol from childhood to adulthood and familial risk of coronary artery disease: the Bogalusa heart study. Atherosclerosis 2001;159:367-373.
32. Clee SM, Loubser O, Collins J, Kastelein JJ, Hayden MR. The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease. Clin Genet 2001;60:293-300.
33. Ross CJ, Twisk J, Meulenberg JM, Liu G, van den Oever K, Moraal E, Hermens WT, Rip J, Kastelein JJ, Kuivenhoven JA, Hayden MR. Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation. Hum Gene Ther 2004;15:906-919.
34. Hozumi Y, Kawano M, Saito T, Miyata M. Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 1998;83:1633-1635.
35. Schmidt HH, Behrens G, Genschel J, Stoll M, Dejam A, Haas R, Manns MP, Schmidt RE. Lipid evaluation in HIV-1-positive patients treated with protease inhibitors. Antivir Ther 1999;4:163-170.
36. Hill JS, Yang D, Nikazy J, Curtiss LK, Sparrow JT, Wong H. Subdomain chimeras of hepatic lipase and lipoprotein lipase. Localization of heparin and cofactor binding. J Biol Chem 1998;273:30979-30984.
37. Shen Y, Lookene A, Nilsson S, Olivecrona G. Functional analyses of human apolipoprotein CII by site-directed mutagenesis identification of residues important for activation of lipoprotein lipase. J Biol Chem 2002;277:4334-4342.
38. Kinnunen PK, Jackson RL, Smith LC, Gotto AM, Jr, Sparrow JT. Activation of lipoprotein lipase by native and synthetic fragments of human plasma apolipoprotein C-II. Proc Natl Acad Sci USA 1977;74:4848-4851.
39. Balasubramaniam A, Rechtin A, McLean LR, Jackson RL, Demel RA. Activation of lipoprotein lipase by N-α-palmitoyl (56-79) fragment of apolipoprotein C-II. Biochem Biophys Res Commun 1986;137:1041-1048.
40. Razzaghi H, Day BW, McClure RJ, Kamboh MI. Structure-function analysis of D9N and N291S mutations in human lipoprotein lipase using molecular modelling. J Mol Graph Model 2001;19:487-494.